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Abstract
Defective clot contraction has been postulated to contribute to thrombosis. We aimed to evaluate the association of residual 
vein obstruction (RVO) with erythrocyte compression within the whole-blood clot. We studied 32 patients with venous 
thromboembolism (VTE) taking vitamin K antagonists (VKAs) for at least 3 months (median time in therapeutic range 
60%), including 12 (37.5%) with RVO, and 32 age- and sex-matched controls. In all study participants we evaluated whole 
blood clot retraction, expressed as the erythrocyte compression index (ECI), defined as a ratio of mean polyhedrocyte area to 
mean native erythrocyte area, along with clot area covered by polyhedrocytes, plasma clot permeability (Ks), clot lysis time 
(CLT), and thrombin generation. In both groups higher ECI, indicating impaired clot contraction, increased with older age, 
higher body mass index, red blood cell distribution width, and lower platelet count (all p < 0.05), but not with red blood cell 
count. In VTE patients ECI was 15.8% higher than in controls (median 63.6 vs. 54.9%, p = 0.021). Subjects with RVO had 
20% higher ECI and 155% lower clot area covered by polyhedrocytes. RVO patients had also prolonged CLT by 41%, but not 
Ks, and elevated peak thrombin generation by 33%, as compared to those without RVO (all p < 0.05). This study is the first 
to show impaired compression of erythrocytes in RVO patients despite VKA anticoagulation. Altered ECI coexisted with 
hypolysability and increased thrombin generation. ECI might be useful in the diagnostic process of RVO or post-thrombotic 
syndrome and can help optimize the anticoagulant therapy.
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Highlights
• The erythrocyte compression index (ECI) is an novel 
measure of clot contraction
• Higher ECI coexists with increased thrombin generation 
and hypofibrinolysis
• ECI increases in patients with residual vein obstruction 
despite anticoagulation
• A prognostic value of clot contraction should be estab-
lished
Introduction
During clot formation, thrombin burst activates platelets 
and converts fibrinogen into fibrin. Fibrin sticks to the acti-
vated platelets via the integrin receptor αIIbβ3 to form a 
platelet–fibrin meshwork comprising the structural basis of 
a hemostatic clot or an obstructive thrombus [1]. When the 
blood clot is formed in vitro in a tube, it undergoes vol-
ume shrinkage, and liquid serum is around compressed clot 
[2]. This process is called clot contraction or retraction [3]. 
Cellular blood components, in particular red blood cells 
(RBCs), platelets, and plasma fibrinogen concentration influ-
ence the rate and extent of clot contraction [3]. Reduced 
clot contraction was associated with a lower platelet count 
and/or their dysfunction, elevated hematocrit, leukocytosis, 
increased plasma fibrinogen, and other changes in blood 
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composition that may affect platelet function and properties 
of blood clots [4]. It has been postulated that defective clot 
retraction might contribute to a tendency to thrombosis [5]. 
Contraction of blood clots has been suggested to be involved 
in the restoration of blood flow in arteries [6]. Tutwiler et al. 
[4] have demonstrated impaired clot contraction in patients 
with acute ischemic stroke associated with platelet dysfunc-
tion [7].
Compressed erythrocytes, called polyhedrocytes due to 
their unique polyhedral shape, have been found in human 
whole blood clots generated in vitro and in human intrac-
oronary thrombi [3, 8]. Polyhedrocyte formation contrib-
utes to the restoration of blood flow in occluded vessels [3, 
5]. Spontaneous restoration of blood flow occurs in venous 
thromboembolism (VTE), but the extent and rate of this 
process have not been reported yet. Residual vein obstruc-
tion (RVO) is observed despite the anticoagulant therapy in 
50% of deep vein thrombosis (DVT) patients and its risk is 
increased in the case of suboptimal anticoagulant therapy, 
delayed diagnosis, iliac vein involvement, unprovoked DVT, 
and thrombophilia [9–11]. Prolonged clot lysis time (CLT) 
and reduced fibrin clot permeability  (Ks) have been found 
to be risk factors for RVO [12]. It is unknown whether RVO 
is associated with impaired clot contraction. We hypothe-
sized that patients with RVO display impaired compression 
of erythrocytes. To address this issue, we developed a new 
approach to assess clot contraction based on the microscopic 
RBC compression in VTE patients using the erythrocyte 
compression index (ECI).
Materials and methods
We enrolled 32 patients with DVT treated with vitamin K 
antagonists (VKAs) for at least 3 months and 32 apparently 
healthy controls with no history of VTE matched for age 
and sex. The diagnosis of DVT was established based on a 
positive finding of color duplex sonography. The exclusion 
criteria were as follows: arterial or venous thromboembolic 
events within previous 6 months, known cancer, signs of 
acute infection, chronic inflammatory disorders, liver injury, 
estimated glomerular filtration rate (eGFR) < 30 mL/min, 
pregnancy. Venous thromboembolism patients were eligi-
ble if they declared regular VKA intake and provided INR 
values measured at least monthly [13]. Time in therapeutic 
range (TTR) was assessed by the Rosendaal method [14]. 
At enrollment we assessed whether or not there was RVO, 
defined as a vein transverse diameter greater than 2 mm or 
as residual thrombus occupying more than 40% of the vein 
area at maximum compressibility [9]. The Jagiellonian Uni-
versity Ethical Committee approved the study and all the 
participants provided their written informed consent.
Routine laboratory investigations
Fasting venous blood was drawn between 7 a.m and 10 a.m. 
and was kept at a room temperature. Blood samples were 
collected into citrated tubes (9:1 of 0.106 M sodium cit-
rate), centrifuged at 2500×g and 20 °C for 10 min, snap-
frozen within 60  min, and stored in small aliquots at 
− 80 °C until analysis. Complete blood count including 
white blood cells (WBC), RBC, hemoglobin, hematocrit, 
RBC distribution width (RDW), platelet count and platelet 
distribution width (PDW) were assayed using the hemato-
logical analyzer Sysmex XT2000i (Sysmex Corporation, 
Kobe, Japan). Fibrinogen was assessed using the Clauss 
method. All patients with VTE were screened for thrombo-
philia. Plasma levels of factor (F)VIII were evaluated using 
FVIII-deficient substrate plasma and the Behring coagula-
tion system (Siemens Healthcare Diagnostics, Marburg, 
Germany).
Preparation of whole blood clots
The clot size after retraction was measured as previously 
described with slight modifications [2]. Clotting was initi-
ated by addition of 40 µL of activation mixture  (CaCl2 and 
human thrombin at final concentrations of 0.01 M and 1 U/
mL, respectively) to 960 µL of prewarmed for 5 min at 37 °C 
citrated whole blood. Samples were incubated at 37 °C for 
1 h and the clot size was measured as a difference between 
the initial sample volume and the fluid volume around the 
clot after its retraction and was expressed as a percentage. 
To provide new insights into the in vitro clot contraction we 
performed analysis of erythrocyte compression inside the 
whole blood clot. Clotting was initiated using the similar 
model as for the clot size measurement in a final volume 
of 50 μL.
Scanning electron microscopy
Scanning electron microscopy (SEM) was performed as 
previously described [15]. Blood clots were washed in 
0.1 M NaCl and fixed in 2.5% glutaraldehyde, dehydrated 
by a graded series of ethanol concentrations and frozen 
in tert-butyl alcohol for 2 h. Then, clots were dried in a 
vacuum and coated with gold. Microphotographs were 
acquired using a scanning electron microscope (JEOL JCM-
6000, Japan). We analyzed 40 images (Fig. 1) for each clot 
and then assessed, using ImageJ (US National Institutes of 
Health), the area (µm2) of native RBCs (mostly observed 
within the clot surface area) and polyhedrocytes (mostly 
located in the internal parts of the clot). Results were 
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presented as means ± standard deviations (SD) of about 
100 consecutive RBC areas obtained from SEM images. 
ECI was defined as a ratio of the mean polyhedrocyte area 
to the mean native RBC area expressed as a percentage 
(Fig. 2). The inter- and intra-observer agreement was 93 
and 95%, respectively.
Fibrin clot characteristics and thrombin generation
Plasma fibrin clot parameters were measured as described 
previously [16]. Briefly,  Ks was assessed using a pressure-
driven system, which indicates the pore size in fibrin net-
works. CLT induced by tissue plasminogen activator added 
Fig. 1  A representative SEM 
image of a retracted whole 
blood clot (magnifications 
×30 and ×3600) used for 
semiquantitative analysis of 
polyhedrocytes content and size 
measurement in 40 selected 
areas located in three vertical 
axes (from the left to the right 
and from the top to the bottom 
of the clot)
Fig. 2  A scheme of erythrocytes 
compression to its polyhedral 
form during in vitro clot forma-
tion
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to plasma with thrombin was determined. Calibrated auto-
mated thrombography was used to measure thrombin gen-
eration, as described [17]. For details see the Supplementary 
Material.
Statistical analysis
The study was powered to have a 90% chance of detect-
ing a 10% difference in clot contraction using a p value 
of 0.01, based on the previous study [4]. In order to dem-
onstrate such a difference or greater, at least five patients 
were required in each group. Categorical variables are pre-
sented as numbers and percentages. Continuous variables 
are expressed as mean ± SD or median and interquartile 
range (IQR). Normality was assessed by the Shapiro–Wilk 
test. Differences between groups were compared using 
the Student’s for normally distributed variables and the 
Mann–Whitney U test was used for non-normally dis-
tributed continuous variables. Categorical variables were 
compared by the Fisher’s exact test. The Spearman’s rank 
correlation coefficient was computed to measure the asso-
ciation between two variables. A two-sided p < 0.05 was 
considered statistically significant. All calculations were 
done with STATISTICA Version 12.5 (StatSoft Inc., Tulsa, 
OK, USA).
Table 1  Characteristics of the study participants
Values are given as mean ± standard deviation or a median (interquartile range), or number (percentage)
aPTT activated partial thromboplastin time, BMI body mass index, CRP C-reactive protein, INR international normalized ratio, LDL-C low 
density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, RVO residual vein obstruction, TG triglycerides, WBC white blood 
cells, Ks fibrin clot permeability, CLT clot lysis time, ETP endogenous thrombin generation
Variables VTE patients (n = 32) Controls (n = 32) p value VTE patients with 





Age (years) 38.5 (33.5–47.5) 39.0 (29.5–43.0) 0.41 36.0 (33.0–48.5) 39.5 (35.0–45.5) 0.74
Male [n (%)] 16 (50) 17 (53) 0.80 7 (58.3) 9 (45) 0.72
BMI (kg/m2) 28.0 ± 6.4 24.4 ± 4.9 0.036 27.6 (24.6–30.0) 28.4 (23.4–31.1) 0.98
Current smoking [n (%)] 5 (15.6) 3 (9.4) 0.45 4 (33.3) 1 (5) 0.053
Laboratory measurements
 INR 2.16 ± 0.86 1.02 ± 0.07 < 0.0001 2.02 (1.44–2.30) 2.34 (1.47–2.77) 0.22
 aPTT (s) 26.2 (24.5–27.3) 35.7 (29.3–39.6) < 0.0001 31.6 (27.1–38.4) 36.2 (31.7–41.0) 0.14
 RBC  (106/µL) 4.84 ± 0.44 4.77 ± 0.34 0.48 4.92 (4.70–5.40) 4.63 (4.41–5.02) 0.11
 WBC  (103/µL) 6.47 (5.3–8.3) 5.95 (5.4–6.6) 0.17 6.5 (5.7–8.8) 7.1 (4.9–8.3) 0.60
 Hemoglobin (g/dL) 14.2 ± 1.5 14.2 ± 1.0 0.95 14.9 (13.7–15.6) 13.6 (12.8–14.6) 0.044
 Hematocrit (%) 42.4 ± 3.6 42 ± 2.6 0.58 44.2 (40.1–46.3) 40.3 (39.2–42.9) 0.040
 RDW (%) 13.3 (12.9–14.2) 12.5 (12.2–13.0) < 0.0001 13.1 (12.8–13.5) 13.5 (13.0–14.5) 0.17
 Platelets  (103/µL) 269 (219–292) 241 (212–279) 0.22 251 (217–284) 271 (222–294) 0.52
 PDW (%) 12.8 ± 2.1 12.9 ± 1.7 0.82 13.3 (11.0–14.5) 12.2 (11.1–13.6) 0.45
 Creatinine (µM) 74 ± 10 79 ± 12 0.13 72 (68–78) 74 (64–81) 0.95
 Glucose (mM) 5.4 ± 0.9 5.0 ± 0.5 0.055 5.2 (4.5–5.5) 5.3 (5.1–5.8) 0.40
 Fibrinogen (g/L) 3.05 (2.86–3.64) 2.53 (2.27–3.20) 0.017 3.04 (2.89–3.58) 3.06 (2.77–3.93) 0.83
 CRP (mg/L) 3.6 (1.0–6.4) 1.5 (0.6–1.4) 0.0022 2.2 (0.6–5.0) 4.2 (2.0–6.8) 0.20
 Total cholesterol (mM) 5.16 (4.36–5.72) 4.56 (4.14–5.19) 0.22 5.16 (4.30–5.90) 5.19 (4.43–5.64) 0.99
 LDL-C (mM) 2.92 (2.52–3.67) 2.86 (2.35–3.52) 0.43 2.92 (2.36–3.68) 3.23 (2.54–3.61) 0.94
 HDL-C (mM) 1.62 ± 0.45 1.62 ± 0.37 0.74 1.57 (1.15–2.03) 1.61 (1.24–1.76) 0.77
 TG (mM) 1.27 (0.95–1.78) 0.91 (0.66–1.14) 0.0026 1.58 (0.94–2.75) 1.27 (0.95–1.73) 0.53
 Ks × 10− 9cm2 5.52 ± 1.26 7.23 ± 1.09 < 0.0001 5.12 (4.25–5.59) 5.43 (4.6–6.72) 0.063
 CLT (min) 109 ± 22 97 ± 14 0.012 135 (103–168) 96 (77–138) < 0.0001
 Lag time (min) 3.3 ± 1.4 5.4 ± 1.6 < 0.0001 3.2 (2.4–4.3) 3.3 (4.4–4.5) 0.78
 ETP (nM × min) 1258 ± 408 1474 ± 146 < 0.01 1241 (910–1409) 945 (521–1382) < 0.01
 Peak thrombin generation ( nM) 294 ± 169 203 ± 64 < 0.0001 302 (161–361) 227 (98–317) 0.032
 Time to peak thrombin (min) 5.0 ± 1.5 8.2 ± 2.5 < 0.0001 5.1 (4.0–7.1) 5.3 (4.1–7.3) 0.81




The VTE patients and control subjects were well matched 
(Table 1). Higher body mass index (BMI) was, however, 
observed in the former group. Factor V Leiden mutation 
was diagnosed in 6 (18.8%) VTE patients, while elevated 
FVIII > 150% was observed in 13 (40.6%) patients. Among 
the VTE patients, 20 (62.5%) subjects were treated with war-
farin and 12 (37.5%) with acenocoumarol with a median 
TTR of 60% (IQR 55–80%). In 18 patients (56%) INR was 
between 2 and 3 [median 2.44 (2.18–2.77)], while in 2 
patients (6%) INR was supratherapeutic and in 12 (37%) 
INR was below two on the day of blood draw. VTE patients 
had higher fibrinogen, CRP, and triglycerides, but not plate-
let count or RBCs (Table 1). VTE patients taking VKAs 
had 23.7% lower  Ks, 12.4% longer CLT, 17.7% lower ETP, 
and 44.8% higher peak thrombin generation compared to 
controls (Table 1). The differences remained significant after 
adjustment for fibrinogen.
Erythrocyte compression index
The new parameter describing compression of erythrocytes, 
ECI, within the whole blood clot was strongly associated 
with the clot size assessed using the previously established 
method (r = 0.44, p < 0.01 for the control group and r = 0.58, 
p < 0.001 for anticoagulated patients). The clot size did 
not differ between control subjects and VTE patients [54 
(50–59.5) vs. 55 (50–63.5)%, p = 0.66, respectively]. How-
ever, ECI was 15.8% higher in VTE patients taking VKAs 
than in controls indicating impaired compression of eryth-
rocytes [63.8 (58.7–69.0) vs. 54.0 (50.0–59.5)%, p = 0.021, 
respectively].
In controls and VTE patients, ECI was related with age, 
BMI, platelet count (Supplementary Fig. 1a–c), and RDW 
(r = 0.47, p = 0.023 and r = 0.53, p = 0.011, respectively), but 
not with RBC count (p > 0.05).
The highest ECI was observed in anticoagulated patients 
with plasma fibrinogen between 3.0 and 4.0 g/L (median 
66.5%) compared with those with fibrinogen between 
2.0 and 3.0 g/L (median, 61.8%) and those below 2.0 g/L 
(median 55.7%) (p < 0.05 for ANOVA). ECI was inversely 
associated with a platelet (× 103/µL)/fibrinogen (g/L) ratio 
in VTE patients (r = − 0.58, p = 0.0013). There were no dif-
ferences in the ECI values regarding sex, smoking, FVIII, 
and CRP (all p > 0.05) in both groups. The clot area cov-
ered by polyhedrocytes [21.3 (8.6–45.0)% in the VKA group 
vs. 30 (15–50) % in controls; p = 0.24] was similar in both 
groups. The median polyhedrocyte size was 8.2% larger in 
VTE patients than in controls [17.1 (15.3–18.5) vs. 15.8 
(10.6–17.0) µm, p = 0.037, respectively].
RVO
Residual vein obstruction was diagnosed in 12 (37.5%) 
DVT patients. RVO patients did not differ from the remain-
der with regard to demographic or routine laboratory 
variables, including fibrinogen and platelet count, except 
slightly higher hemoglobin and hematocrit in the former 
group (Table 1). Subjects with RVO had 20% higher ECI 
(Fig. 3), also after adjustment for hemoglobin or hemato-
crit, and 155% lower clot area covered by polyhedrocytes 
[12.5 (5.0–17.5) vs. 31.9 (15.0–52.5)%, p = 0.025]. The clot 
size however did not differ between patients with and with-
out RVO (p > 0.05). RVO patients had also prolonged CLT 
by 41%, but not  Ks, and elevated ETP by 31.3% and peak 
thrombin generation by 33%, as compared to those without 
RVO (Table 1).
Discussion
This study is the first to show that the clot contraction is 
impaired in patients with RVO despite anticoagulation. We 
provided evidence for the concept that the clot contraction 
contributes to the restoration of blood flow in veins and its 
impairment predisposes to RVO. Our findings suggest that 
contraction of clots might have identify patients at risk of 
such common complication of DVT and possibly also at 
risk of recurrent ipsilateral thrombosis [18]. Formation of 
deep venous thrombi is a dynamic process, which in 45% of 
subjects results in incomplete vein recanalization within 6–9 
months of thrombosis [19]. Most of these changes occur dur-
ing the first 3 months after DVT, while the clot structure and 
Fig. 3  ECI in patients with or without residual vein obstruction 
(RVO). Horizontal lines denote medians
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function at the DVT onset can predict recurrent thrombosis 
and its outcome [20]. We hypothesize that the clot ability to 
contract is a characteristic blood feature of each patient and 
can undergo modulation mediated by transient factors [21], 
however even after a few months since thrombosis and on 
anticoagulation, impaired clot contraction can be observed 
and influences the fate of thrombotic material in the vascular 
lumen.
From a methodological point of view, we have introduced 
the novel parameter describing the extent of RBCs com-
pression within the clot, i.e. the ECI. Although this variable 
appears to have no clinical utility, at least for now, it may 
facilitate assessment of some modulators of clot contraction, 
particularly in patients with thromboembolic disorders. In 
our study, ECI showed positive associations—in both VTE 
patients and controls—with older age, higher BMI, and 
RDW, suggesting that in these conditions clot contraction is 
impaired. We found also that ECI was inversely associated 
with platelet count, in both studied groups, while a correla-
tion of ECI with fibrinogen was observed in VTE patients 
only. Tutwiler et al. [4] presented similar effects of differ-
ent platelet counts and fibrinogen levels on clot contrac-
tion. Increased platelet count results in faster clot retraction 
depending on contractile forces generated by the platelet 
cytoskeleton [22], while fibrin is essential for transmitting 
those forces between platelets [3]. Our data suggest that the 
contraction of the whole blood clot depends also on the size 
of RBCs trapped within the fibrin network. Thus anisocy-
tosis could be one of the factors facilitating clot contrac-
tion through better RBCs fitting. Higher RDW values were 
associated with adverse clinical outcomes in patients with 
heart failure, coronary artery disease, or stroke [23–25]. 
Very recent data showed that the platelet packing density 
can regulate platelet activation and thus determine the clot 
architecture and retraction [26]. Platelet volume, PDW, and 
RDW-platelet ratio have been shown to be associated with 
the no-reflow phenomenon and cardiovascular complications 
in patients with ST-elevation myocardial infarction [27, 28]. 
Moreover, inflammation might play an important role in 
increased RDW values by promoting the release of imma-
ture RBCs into the circulation [29], thus might contribute to 
the impaired clot contraction. ECI might be useful in some 
specific circumstances for example in subjects with iron defi-
ciency [30] or thrombocythemia [31]. We hypothesize that 
erythrocytes of similar sizes are more likely to form polyhe-
drocytes, while different sizes of RBCs hamper this process. 
Therefore, increased RDW would result in poorer ability of 
erythrocytes to provide an impermeable seal, due to minimal 
interstitial space, to increase fibrinolysis resistance.
During the clot formation, increasing levels of thrombin 
and/or fibrinogen have been shown to alter fibrin clot prop-
erties [32, 33]. We found that ECI was associated rather 
with the platelet/fibrinogen ratio, than with platelet count 
or fibrinogen alone, which is in line with the study by Cines 
et al. [3], who showed that at low fibrinogen levels a higher 
platelet count is required. This observation highlights a 
platelet-driven, fibrin-mediated mechanism of clot contrac-
tion [34]. The association of clot contraction with fibrin 
plasma clot lysability deserves a comment. Carroll et al. 
[5] showed that platelet-mediated clot contraction facili-
tated clot lysis suggesting an important effect of platelets 
in clot retraction. Our results extended this observation by 
showing that impaired clot contraction coexisted with pro-
longed CLT, which could be clinically relevant, since CLT 
has been reported as a risk factor for both venous and arte-
rial thrombosis and recurrent VTE [16, 35–37]. It might be 
speculated that assessment of clot contraction, using ECI or 
possibly other measures can help identify individuals of risk 
of RVO. Given evidence for association between RVO and 
post-thrombotic syndrome as well as DVT recurrence, ECI 
might possibly be useful in the assessment and optimization 
of anticoagulant therapy. Further long-term follow-up stud-
ies are warranted to validate this hypothesis.
This study has several limitations. First, the sample size 
was limited and presented observations must be interpreted 
with caution. However, analyses were sufficiently powered 
and it is unlikely that the differences reported here result 
from a significant bias. Second, the relevance of clot con-
traction should be confirmed in vivo. However, impaired 
ECI in VTE patients with RVO supports our hypotheses. A 
prognostic value of clot contraction and its markers like ECI 
remains to be established.
The main finding of our work is that the whole blood clot 
contraction assessed in VTE patients with RVO is impaired 
even when assessed during anticoagulant therapy. Addition-
ally, we found that altered clot contraction coexisted with 
increased thrombin generation and impaired susceptibility to 
fibrinolysis. Those data indicate that besides prothrombotic 
fibrin clot phenotype, clot contraction might be of major 
importance in thromboembolic disorders and regulation of 
this process appears to be much more complicated than one 
would have expected. Given a role of platelets in clot con-
traction and data shown by Rusak et al. [22] that tirofiban—a 
platelet glycoprotein IIb/IIIa inhibitor significantly reduced 
clot retraction, it seems that antiplatelet agents might 
improve clot retraction at least to some extent. Further stud-
ies are needed to clarify these complex associations.
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